$2.40 Million in Sales Expected for Curis, Inc. (CRIS) This Quarter

Share on StockTwits

Wall Street analysts predict that Curis, Inc. (NASDAQ:CRIS) will post $2.40 million in sales for the current quarter, Zacks reports. Two analysts have issued estimates for Curis’ earnings. The lowest sales estimate is $2.29 million and the highest is $2.50 million. Curis posted sales of $3.26 million during the same quarter last year, which suggests a negative year over year growth rate of 26.4%. The company is scheduled to announce its next quarterly earnings results on Thursday, March 14th.

On average, analysts expect that Curis will report full year sales of $10.19 million for the current year, with estimates ranging from $9.97 million to $10.40 million. For the next financial year, analysts expect that the business will post sales of $10.79 million, with estimates ranging from $9.48 million to $12.10 million. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that cover Curis.

Curis (NASDAQ:CRIS) last announced its earnings results on Thursday, November 1st. The biotechnology company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.09. The business had revenue of $2.85 million for the quarter, compared to the consensus estimate of $2.38 million. Curis had a negative return on equity of 299.20% and a negative net margin of 316.98%.

Several research analysts have recently commented on CRIS shares. Zacks Investment Research raised Curis from a “hold” rating to a “buy” rating and set a $2.00 target price on the stock in a report on Wednesday, August 8th. Cowen reissued a “buy” rating on shares of Curis in a report on Monday, August 6th. Finally, SunTrust Banks reduced their target price on Curis to $8.00 and set a “buy” rating on the stock in a report on Friday, August 3rd. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $13.33.

Shares of CRIS traded down $0.11 on Monday, hitting $1.56. The company’s stock had a trading volume of 220,084 shares, compared to its average volume of 301,291. The company has a market capitalization of $52.65 million, a P/E ratio of -0.87 and a beta of 1.16. The company has a debt-to-equity ratio of 38.74, a current ratio of 2.63 and a quick ratio of 2.63. Curis has a fifty-two week low of $1.36 and a fifty-two week high of $7.17.

Several institutional investors and hedge funds have recently made changes to their positions in the company. JPMorgan Chase & Co. boosted its holdings in shares of Curis by 780.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 73,954 shares of the biotechnology company’s stock worth $132,000 after acquiring an additional 65,554 shares in the last quarter. LMR Partners LLP acquired a new position in shares of Curis in the 2nd quarter worth approximately $124,000. Paloma Partners Management Co acquired a new position in shares of Curis in the 2nd quarter worth approximately $223,000. Finally, Millennium Management LLC acquired a new position in shares of Curis in the 2nd quarter worth approximately $540,000. 33.51% of the stock is currently owned by institutional investors and hedge funds.

About Curis

Curis, Inc, a biotechnology company, focuses on the development and commercialization of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CUDC-907, an oral dual inhibitor of HDAC and PI3K enzymes, which is in Phase II clinical trial for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trial for treating patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers.

Featured Article: How accurate is the Rule of 72?

Get a free copy of the Zacks research report on Curis (CRIS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Curis (NASDAQ:CRIS)

Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.